Press Releases.

Proceeds Used to Repay Debt Principal with Oxford Finance

Completion of Dosing in Phase 1 Multiple Ascending Dose Study ("MAD") of RGLS4326 in Healthy Volunteers for Autosomal Dominant Polycystic Kidney Disease ("ADPKD")

Initiated Third and Final Cohort of the Multiple Ascending Dose Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

FDA Removal of Partial Clinical Hold for Phase I Multiple Ascending Dose Study of RGLS4326

Regulus Plans to Re-Initiate Clinical Studies in Q1 2020

Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326

Closing of First Tranche of $41.8 Million Private Placement of Equity

Data Requirements Defined To Reinitiate Multiple Ascending Dose And Chronic Dose Studies With RGLS4326

Closing of First Tranche of $41.8 Million Private Placement of Equity